For this aim, we conducted a cohort study by enrolling the consecutive RA patients treated by biologics in our cohort, and analyzed the effect of TCZ therapy with potential confounders for the increase of Hb levels. The gene discussed is GSTM1; the disease is rheumatoid arthritis.